# Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

> **NCT01230021** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 6 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Congenital FXIII Deficiency

## Interventions

- **DRUG:** catridecacog

## Key facts

- **NCT ID:** NCT01230021
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01230021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01230021, "Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01230021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*